Results 201 to 210 of about 49,657 (223)

HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012-19: a population-based, longitudinal study.

Lancet Microbe
Martin MA, Reynolds SJ, Foley BT, Nalugoda F, Quinn TC, Kemp SA, Nakalanzi M, Kankaka EN, Kigozi G, Ssekubugu R, Gupta RK, Abeler-Dörner L, Kagaayi J, Ratmann O, Fraser C, Galiwango RM, Bonsall D, Grabowski MK, Rakai Health Sciences Program Members, PANGEA-HIV Members.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Nature, 2020
Ugur Sahin, Petra Oehm, Mathias Vormehr
exaly